Emergent BioSolutions cuts 2026 revenue and EBITDA guidance as Q3 sales fall 52%Nov 2Quarterly updateAmgenAprea Therapeutics
OPKO Health agrees to sell lab testing assets to LabCorp for up to $872 millionOct 15M&AOPKO Health, Inc.
OPKO Health says its 2029 convertible notes are now convertible through year-endOct 2FinancingOPKO Health, Inc.
OPKO Health amends note agreement, issues $125 million in additional senior secured notesAug 14FinancingOPKO Health, Inc.
OPKO reports Q2 2026 results with multiple pipeline milestones across ModeX and OPKO BiologicsJul 27Quarterly updatecalcifediolOPKO Health, Inc.